H. pylori modulates DC functions via T4SS/TNFα/p38-dependent SOCS3 expression.
Antigens, Bacterial
/ metabolism
B7-H1 Antigen
/ metabolism
Bacterial Proteins
/ metabolism
Bacterial Secretion Systems
Cell Proliferation
Chemokines
/ metabolism
Dendritic Cells
/ metabolism
Feedback, Physiological
Helicobacter Infections
/ metabolism
Helicobacter pylori
/ physiology
Humans
Janus Kinases
/ metabolism
Mitogen-Activated Protein Kinase Kinases
/ metabolism
Monocytes
/ metabolism
Mutation
/ genetics
Phosphorylation
Signal Transduction
Suppressor of Cytokine Signaling 3 Protein
/ metabolism
Toll-Like Receptors
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ metabolism
Dendritic cell
H. Pylori
SOCS
Type IV secretion system
p38
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
received:
02
03
2020
accepted:
06
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
12
8
2021
Statut:
epublish
Résumé
Helicobacter pylori (H. pylori) is a gram-negative bacterium that chronically infects approximately 50% of the world's human population. While in most cases the infection remains asymptomatic, 10% of infected individuals develop gastric pathologies and 1-3% progress to gastric cancer. Although H. pylori induces severe inflammatory responses, the host's immune system fails to clear the pathogen and H. pylori can persist in the human stomach for decades. As suppressor of cytokine signaling (SOCS) proteins are important feedback regulators limiting inflammatory responses, we hypothesized that H. pylori could modulate the host's immune responses by inducing SOCS expression. The phenotype of human monocyte-derived DCs (moDCs) infected with H. pylori was analyzed by flow cytometry and multiplex technology. SOCS expression levels were monitored by qPCR and signaling studies were conducted by means of Western blot. For functional studies, RNA interference-based silencing of SOCS1-3 and co-cultures with CD4 We show that H. pylori positive gastritis patients express significantly higher SOCS3, but not SOCS1 and SOCS2, levels compared to H. pylori negative patients. Moreover, infection of human moDCs with H. pylori rapidly induces SOCS3 expression, which requires the type IV secretion system (T4SS), release of TNFα, and signaling via the MAP kinase p38, but appears to be independent of TLR2, TLR4, MEK1/2 and STAT proteins. Silencing of SOCS3 expression in moDCs prior to H. pylori infection resulted in increased release of both pro- and anti-inflammatory cytokines, upregulation of PD-L1, and decreased T-cell proliferation. This study shows that H. pylori induces SOCS3 via an autocrine loop involving the T4SS and TNFα and p38 signaling. Moreover, we demonstrate that high levels of SOCS3 in DCs dampen PD-L1 expression on DCs, which in turn drives T-cell proliferation. Video Abstract.
Sections du résumé
BACKGROUND
Helicobacter pylori (H. pylori) is a gram-negative bacterium that chronically infects approximately 50% of the world's human population. While in most cases the infection remains asymptomatic, 10% of infected individuals develop gastric pathologies and 1-3% progress to gastric cancer. Although H. pylori induces severe inflammatory responses, the host's immune system fails to clear the pathogen and H. pylori can persist in the human stomach for decades. As suppressor of cytokine signaling (SOCS) proteins are important feedback regulators limiting inflammatory responses, we hypothesized that H. pylori could modulate the host's immune responses by inducing SOCS expression.
METHODS
The phenotype of human monocyte-derived DCs (moDCs) infected with H. pylori was analyzed by flow cytometry and multiplex technology. SOCS expression levels were monitored by qPCR and signaling studies were conducted by means of Western blot. For functional studies, RNA interference-based silencing of SOCS1-3 and co-cultures with CD4
RESULTS
We show that H. pylori positive gastritis patients express significantly higher SOCS3, but not SOCS1 and SOCS2, levels compared to H. pylori negative patients. Moreover, infection of human moDCs with H. pylori rapidly induces SOCS3 expression, which requires the type IV secretion system (T4SS), release of TNFα, and signaling via the MAP kinase p38, but appears to be independent of TLR2, TLR4, MEK1/2 and STAT proteins. Silencing of SOCS3 expression in moDCs prior to H. pylori infection resulted in increased release of both pro- and anti-inflammatory cytokines, upregulation of PD-L1, and decreased T-cell proliferation.
CONCLUSIONS
This study shows that H. pylori induces SOCS3 via an autocrine loop involving the T4SS and TNFα and p38 signaling. Moreover, we demonstrate that high levels of SOCS3 in DCs dampen PD-L1 expression on DCs, which in turn drives T-cell proliferation. Video Abstract.
Identifiants
pubmed: 33023610
doi: 10.1186/s12964-020-00655-1
pii: 10.1186/s12964-020-00655-1
pmc: PMC7541176
doi:
Substances chimiques
Antigens, Bacterial
0
B7-H1 Antigen
0
Bacterial Proteins
0
Bacterial Secretion Systems
0
CD274 protein, human
0
Chemokines
0
Suppressor of Cytokine Signaling 3 Protein
0
Toll-Like Receptors
0
Tumor Necrosis Factor-alpha
0
cagA protein, Helicobacter pylori
0
Janus Kinases
EC 2.7.10.2
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Subventions
Organisme : Austrian Science Fund FWF
ID : P 29941
Pays : Austria
Références
Helicobacter. 2009 Jun;14(3):208-22
pubmed: 19702851
Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G73-81
pubmed: 16469828
PLoS Pathog. 2011 Dec;7(12):e1002454
pubmed: 22216004
J Immunol. 2012 Aug 1;189(3):1182-92
pubmed: 22753940
J Immunol. 2006 Aug 1;177(3):1679-88
pubmed: 16849477
J Immunol. 2001 Feb 1;166(3):1938-44
pubmed: 11160242
Mucosal Immunol. 2010 May;3(3):260-9
pubmed: 20237463
FEMS Microbiol Lett. 2001 Mar 15;196(2):235-8
pubmed: 11267785
J Immunol. 2004 Jul 15;173(2):1249-57
pubmed: 15240717
Nat Biotechnol. 2004 Dec;22(12):1546-53
pubmed: 15558048
J Biol Chem. 2004 Dec 24;279(52):54708-15
pubmed: 15491991
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
N Engl J Med. 2001 Sep 13;345(11):784-9
pubmed: 11556297
J Immunol. 2008 Mar 15;180(6):4040-9
pubmed: 18322213
Mol Microbiol. 2000 Jun;36(6):1187-96
pubmed: 10931272
J Biol Chem. 2011 Jul 29;286(30):26873-87
pubmed: 21622562
Cell Commun Signal. 2013 Oct 07;11:77
pubmed: 24099599
J Immunol. 2003 Feb 1;170(3):1257-66
pubmed: 12538684
Front Microbiol. 2017 Dec 12;8:2431
pubmed: 29312162
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Infect Immun. 2012 Aug;80(8):2724-34
pubmed: 22615251
J Immunol. 2007 Nov 1;179(9):5966-76
pubmed: 17947670
Cell Microbiol. 2015 Jan;17(1):51-61
pubmed: 25087912
Nat Rev Cancer. 2002 Jan;2(1):28-37
pubmed: 11902583
Ann Intern Med. 1991 Apr 15;114(8):662-3
pubmed: 2003713
Cell Rep. 2017 Sep 5;20(10):2384-2395
pubmed: 28877472
J Biol Chem. 1999 Apr 16;274(16):10689-92
pubmed: 10196138
Infect Immun. 2005 Jul;73(7):4180-9
pubmed: 15972508
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9247-52
pubmed: 15956202
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
PLoS One. 2014 Aug 25;9(8):e104804
pubmed: 25153703
Front Microbiol. 2014 Jul 18;5:356
pubmed: 25101063
Blood. 2006 Dec 15;108(13):4102-8
pubmed: 16896155
Mol Cell Biochem. 2006 Aug;288(1-2):179-89
pubmed: 16718380
J Exp Med. 2017 Sep 4;214(9):2523-2533
pubmed: 28710273
J Immunol. 2001 Jun 15;166(12):7082-9
pubmed: 11390452
Infect Immun. 2005 Nov;73(11):7332-9
pubmed: 16239531
Clin Microbiol Rev. 2006 Jul;19(3):449-90
pubmed: 16847081
Sci Rep. 2017 Apr 21;7(1):1005
pubmed: 28432285
J Cell Sci. 2004 Mar 15;117(Pt 8):1281-3
pubmed: 15020666
Infect Immun. 2010 Feb;78(2):845-53
pubmed: 19917709
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3047-52
pubmed: 23382221
Blood Adv. 2017 Jul 21;1(17):1324-1334
pubmed: 29296775
Gut. 2004 Sep;53(9):1235-43
pubmed: 15306577
Immunol Res. 2015 Mar;61(3):206-18
pubmed: 25381480
J Immunol. 2011 Sep 15;187(6):2875-84
pubmed: 21844389
Helicobacter. 2008 Apr;13(2):112-26
pubmed: 18321301
PLoS Pathog. 2017 Jul 17;13(7):e1006514
pubmed: 28715499
PLoS Pathog. 2018 Jan 16;14(1):e1006809
pubmed: 29338039
J Infect Dis. 2000 Jan;181(1):273-82
pubmed: 10608776
Clin Exp Immunol. 2010 Sep;161(3):551-9
pubmed: 20646001
J Immunol. 1999 Nov 15;163(10):5552-9
pubmed: 10553083
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5024-9
pubmed: 15044704
J Immunol. 2005 Mar 1;174(5):2494-8
pubmed: 15728454
Biochem J. 2000 Jul 1;349(Pt 1):99-104
pubmed: 10861216
IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
pubmed: 7715068
J Immunol. 2007 Mar 1;178(5):2813-26
pubmed: 17312125
Infect Immun. 2004 Aug;72(8):4416-23
pubmed: 15271898
World J Gastroenterol. 2012 Sep 28;18(36):5101-5
pubmed: 23049221
FASEB J. 2019 Aug;33(8):9087-9099
pubmed: 31075211
mBio. 2019 Mar 19;10(2):
pubmed: 30890606
Infect Immun. 2005 May;73(5):2999-3006
pubmed: 15845507
Pathog Dis. 2013 Feb;67(1):46-53
pubmed: 23620119
Nat Rev Immunol. 2007 Jun;7(6):454-65
pubmed: 17525754
Clin Exp Immunol. 2011 Jul;165(1):94-103
pubmed: 21545585